Eser, SultanGoksel, TuncayErbaycu, Ahmet EminBaydur, HakanBasarik, BurcuYanik, Aysen OzGursul, Kader Kiyar2024-06-122024-06-1220162193-1801https://doi.org/10.1186/s40064-016-3492-7https://hdl.handle.net/20.500.14551/22224Background: Our purpose is to examine the relationship of Health related quality of life measured by EORTC QLQc30, QLQ-LC13; FACT-L, LCSS, Eq5D) with survival in advanced lung cancer patients. A total of 299 Lung Cancer (LC) patients were, included in this national multicenter Project entitled of the LC Quality of Life Project (AKAYAK). Baseline scores were analyzed by using Cox's proportional hazard regression to identify factors that influenced survival. Univariate and multivariate models were run for each of the scales included in the study. Results: Mean and median survival were 12.5 and 8.0 months respectively. Clinical stage (as TNM), comorbidity; symptom scales of fatigue, insomnia, appetit loss and constipation were associated with survival after adjustment for age and sex. Global, physical and role functioning scales of QLQc30; physical and functional scales of LCS and TOI of the FACT-L was also associated with survival. Mobility and Usual activities dimensions of the Eq5D; Physical functioning and the constipation symptom scale of the QLQ-c30; and LCS and TOI scores of the FACT-L remained statistically significant after adjustment. LC13 and LCSS scales were not predictors of survival. Conclusions: HRQOL serves as an additional predictive factor for survival that supplements traditional clinical factors. Besides the strong predictive ability of ECOG on survival, FACT-L and the Eq5D are the most promising HRQOL instruments for this purpose.en10.1186/s40064-016-3492-7info:eu-repo/semantics/openAccessLung CancerHRQOLPrognostic FactorsSurvivalCooperative-Oncology-GroupPrognostic-FactorsEuropean-OrganizationClinical-TrialsEortc Qlq-C30Receiving ChemotherapyFunctional AssessmentPerformance StatusReported HealthQuestionnaireArticle5Q2WOS:0003918109000132-s2.0-8499176489127818871N/A